Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
By Monalisa Breazu, Learning & Development Administrator
In the life sciences sector, we talk a lot about innovation, regulation, and breakthroughs, but how often do we stop to think about how well the entire organisation understands the journey from lab bench to market launch?
by Tony Jones, CEO, One Nucleus
To mark the 25th anniversary of the Tyndall Centre for Climate Change Research, the University of East Anglia (UEA), which leads the Tyndall Centre, is holding its largest ever climate conference. Many of the brightest minds on climate change are attending to discuss the ‘critical decade for climate action’ ahead of us and to discuss what university research needs to happen in the next five years that is truly useful for climate change action.
Timely access to high-quality peptides is essential in drug discovery, especially for screening, structure-activity relationship (SAR) studies, and early-stage preclinical research. Any delay in peptide synthesis can slow down critical experiments, affect project timelines, and limit the ability to make rapid decisions in lead optimisation.
– Reassure Pregnancy is being used to monitor signs of pre-eclampsia in two NHS hospitals –
– Camgenium is pioneering the development of software to ensure high-quality antenatal care is accessible to all women –
Your role
As a Postdoctoral Fellow on the NeuroImmune Open Targets project, you will develop and apply integrative computational pipelines to dissect immune-cell phenotypes and cell–cell interactions across Alzheimer’s, Parkinson’s, and Amyotrophic lateral sclerosis patient tissues and matched induced pluripotent stem cells models.
Your group
Saez-Rodriguez Research Group in collaboration with Open-Targets
Your supervisor
Julio Saez-Rodriguez
You will
Join us for the upcoming o2h ChaiTime Webinar, where our expert panellists will discuss how MFN pricing could reshape R&D strategies, operations, decision-making for biotech and pharma.
The biopharma landscape is shifting fast, driven by evolving pricing policies, geopolitical trade tensions, and mounting pressure to optimise R&D investment. With the recent push toward nation-based drug pricing, global companies are being forced to rethink not just pricing models, but where and how they innovate.
Cancer Research Horizons, the innovation arm of Cancer Research UK, has appointed its first Clinical Advisory Board to provide strategic guidance on the development of novel cancer therapeutics emerging from its drug discovery division, Therapeutic Innovation.
Devens, MA, USA — Veranova is pleased to announce the appointment of Dr. Matteo Villain as Vice President of Peptides and Oligonucleotides. Dr. Villain will bring extensive expertise in peptide and oligonucleotide development and manufacturing to Veranova as the company continues to strengthen its position as a key player in the Peptide and Oligonucleotide (TIDES) space.